Baird Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jeff Johnson maintains a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $36 to $39.

August 02, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Jeff Johnson maintains a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $36 to $39.
The raised price target from $36 to $39 suggests a positive outlook on the stock, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see significant upside potential beyond the new target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100